QCG
ABEO icon

Quadrant Capital Group’s Abeona Therapeutics ABEO Stock Holding History

Quadrant Capital Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-667
Closed -$3.52K – 2707
2025
Q3 		$3.52K Buy
+667
New +$4.23K ﹤0.01% 2382

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Quadrant Capital Group's ABEO Position: Q4 2025 in Review

Quadrant Capital Group sold out of Abeona Therapeutics (ABEO) in Q4 2025, closing a stake of 667 shares — an estimated $3.52K sold.

Quadrant Capital Group first reported a position in ABEO in Q3 2025 and held it in 1 quarter. The position peaked at $3.52K in Q3 2025. 104 funds tracked by Wall St. Rank hold ABEO as of Q4 2025.

  • Quadrant Capital Group reported no remaining Abeona Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 667 Abeona Therapeutics shares in Q4 2025, an estimated $3.52K.
  • Quadrant Capital Group first reported a position in Abeona Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrant Capital Group's Abeona Therapeutics position peaked at $3.52K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2025.

Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.